Antibodies to Factor XII Associated with Lupus Anticoagulant

Summary

Falsely low levels of factor XII (FXII) have been documented in patients who are lupus anticoagulant positive (LA+). In addition, we have previously noted a surprisingly high incidence (20.9%) of apparently true FXII deficiency in patients who were LA+. We have hypothesised that this may be partly due to the presence of antibodies to FXII.

The aim of the present study was to investigate whether LA+ patient plasmas contain antibodies directed either against FXII or FXII in association with phospholipids. Plasma samples from 60 blood donors, all LA negative, and 51 LA+ patients were tested using ELISA assays employing purified FXII, phosphatidylserine (PS) and phosphatidylethanolamine (PE). We have identified seven patients whose plasma contained either IgG or IgM that reacted with purified FXII in the absence of PS or PE. When PS was included in the assay system four additional patient plasmas were shown to contain either IgG or IgM that reacted with FXII. The plasma of one patient contained IgG that reacted with FXII both in the presence and absence of PS. There was no reactivity to FXII with either IgG or IgM when PE was included in the assay system. Affinity purified IgG from three patients whose plasma reacted with FXII in the ELISA assay in the absence of PS, gave a positive reaction in an immunoblot assay. These results suggest that FXII antibodies are present in a significant proportion of LA+ patients and may lead to an erroneous diagnosis of FXII deficiency.

• References

• 1 Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4.
• 2 Galli M, Comfurius P, Massen C, Hemker HC, De Baets MH, van BredaVriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
• 3 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
• 4 Fleck RA, Rapaport I S, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-9.
• 5 Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognise a kininogen-PE complex. Blood 1995; 86: 3083-9.
• 6 Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in kininogens recognisable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76: 354-60.
• 7 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Sem Thromb Haemost 1987; 13: 50-68.
• 8 Levi M, Hack CE, de Boer JP, Brandjes DPM, Buller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. J Clin Invest 1991; 88: 1155-60.
• 9 Smith O, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-9.
• 10 Egberg N, Gallimore MJ, Green K, Jacobsson J, Vesterqvist O, Wiman B. Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostacyc-line metabolites. Fibrinolysis 1988; 2: 101-6.
• 11 Mannhalter C, Fischer M, Hoppmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering recurrent thrombosis. Fibrinolysis 1987; 1: 259-63.
• 12 Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated patients suffering from venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
• 13 Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency – a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-21.
• 14 Rodeghiero F, Castaman G, Ruggieri M, Tusetto A. Thrombosis in subjects with homozygous and heterozygous factor XII deficiency. Thromb Haemost 1992; 67: 590.
• 15 Winter M, Gallimore M, Jones DW. Should factor XII assays be included in thrombophilia screening?. Lancet 1995; 346: 52.
• 16 Jones DW, Gallimore MJ, Winter M. Pseudo factor XII deficiency and phospholipid antibodies. Thromb Haemost 1996; 75: 696-7.
• 17 Gallimore MJ, Jones DW, Winter M. Factor XII determinations in the presence and absence of phospholipid antibodies. Thromb Haemost 1998; 79: 87-90.
• 18 Jones DW, Gallimore MJ, Winter M. An automated chromogenic peptide substrate assay for coagulation factor XII. Blood Coag Fibrinol 1998; 9: 183-7.
• 19 The British Society for Haematology. Guidelines on testing for lupus anticoagulant. J Clin Path 1991; 44: 885-9.
• 20 Åberg H, Nilsson IM. Recurrent thrombosis in a young woman with a cir culating anticoagulant directed against FXI and FXII. Acta Med Scand 1972; 192: 419-25.
• 21 Davis S, Furie BC, Griffin JH, Furie B, Willey R. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. Am J Hematol 1978; 4: 401-7.
• 22 Jaeger U, Kapiotis S, Pabinger I, Puchhammer E, Kryle PA, Lechner K. Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection. Ann Hematol 1993; 67: 95-9.